The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and on Gut Microbiota in Subjects With Functional Constipation: A Randomized, Placebo-Controlled Pilot Trial
Primary Purpose
Functional Constipation
Status
Recruiting
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
Carbonated Natural Mineral Water
Low Mineral Water
Sponsored by
About this trial
This is an interventional prevention trial for Functional Constipation
Eligibility Criteria
Inclusion Criteria:
- Age between 18 to 70
- Having Functional Constipation diagnosis criteria, according to the Rome IV criteria
- Not using any laxative drug for 3 days before screening visit
- Drinking 1.0 ± 0.5 L of water per day
- Accept and sign the consent
Exclusion Criteria:
- Treatment or disease (current or past) likely to interfere with evaluation of the study parameters
- Taking antibiotics in the 3 months preceding the recruitment visit
- Taking supplements and any food enriched or presented containing bacteria or yeasts likely to have an effect on the gastrointestinal tract, particularly on intestinal transit, digestive comfort, gas production, the occurrence of abdominal pain in the 30 days preceding the recruitment visit (these products will also be banned during the study period)
- Subject having an alcohol consumption of more than 3 glasses of wine a day, or 2 glasses of beer a day, or 1 glass of hard liquor a day
- Subject having a coffee consumption greater than 5 cups per day
- Subject with constipation attributable to an organic or anatomical cause (Hirschsprung's disease, hypothyroidism, mental deficiency, psychiatric illness, neurological abnormalities, history of operation of the colon or anus, colorectal cancer, anemia, etc.)
- Subject with a history of current gastrointestinal pathology or disorder such as duodenal ulcer, chronic colitis, or chronic inflammatory disease of the gastrointestinal tract (Crohn's disease, ulcerative colitis), celiac disease or syndrome irritable bowel
- Subject having a history of operation of the digestive tract
- Subject having undergone surgery in the two months preceding the recruitment visit
- Subject having undergone bariatric surgery
- History of renal disease (renal insufficiency etc.) or cardiovascular disease (cardiac insufficiency...), respiratory disease, neural disease
- Having participated in a weight loss program (with a 5-10% weight) loss in the last 3 months prior to the recruitment visit
- Body mass index > 35 kg/ m2
- Taking supplements of magnesium, vitamins, or other minerals during the study period
- Intake of other carbonated mineral waters beyond the given water, during the study period.
- Pregnancy
- Participation in another clinical trial during the last 30 days prior to the recruitment visit
Sites / Locations
- NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVARecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Carbonated Natural Mineral Water
Low Mineral Water
Arm Description
750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium and magnesium.
750 mL/day of low mineral water.
Outcomes
Primary Outcome Measures
Difference between the intervention and control group in the change in gastrointestinal transit from baseline to the end of follow-up (4 weeks).
Change in gastrointestinal transit measured by the percentage of responder subjects defined as a composite score of the two following Rome IV criteria: number of stools ≥ 4 or an increase of 2 stools/week and stools consistency with less than 25% of lumpy to hard stools.
Secondary Outcome Measures
Difference between the intervention and control group in the change in stool consistency from baseline to the end of follow-up (4 weeks).
Change in stool consistency measured using Bristol scale.
Difference between the intervention and control group in the change in constipation symptoms from baseline to the end of follow-up (4 weeks).
Change in constipation symptoms measured using a validated PAC-SYM questionnaire. PAC-SYM is a 12-item, self-administered questionnaire used to measure severity of symptoms over the past 2 weeks in patients with constipation. Cultural adaptation and linguistic validation of the PAC-SYM for Portugal was performed by Mapi Research.
Difference between the intervention and control group in the change in constipation Quality of Life from baseline to the end of follow-up (4 weeks).
Change in constipation Quality of Life measured using a validated PAC-QOL questionnaire. PAC-QOL questionnaire is a 28-item self-administered questionnaire that is being used to measure health-related quality of life (over the past 2 weeks) in patients with chronic constipation. Cultural adaptation and linguistic validation of the PAC-QOL for Portugal was performed by Mapi Research Trust.
Difference between the intervention and control group in the change in Perceived Stress Scale from baseline to the end of follow-up (4 weeks).
Change in constipation Perceived Stress Scale measured using a validated Perceived Stress Scale questionnaire. A validated Perceived Stress Scale (PSS) self-administered questionnaire with 13-item will be used to measure perceived stress of respondents during the last month (Portuguese version keeps 13 of the 14 original items). The PSS questionnaire has been demonstrated to have internal consistency, reproducibility, validity, and sensitivity. Cultural adaptation and linguistic validation of the PSS for Portugal was implemented by Pais-Ribeiro & Marques (2009).
Difference between the intervention and control group in the change in gut microbiota from baseline to the end of follow-up (4 weeks).
Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.
Difference between the intervention and control group in the change in short-chain fatty acid profiling from baseline to the end of follow-up (4 weeks).
Change in short-chain fatty acid profiling evaluated by the faeces concentration of short-chain fatty acids before and after intervention.
Difference between the intervention and control group in the change in urinary excretion of minerals from baseline to the end of follow-up (4 weeks).
Change in urinary excretion of minerals evaluated by the K+, Na+, Mg2+ and Ca2+ excretion before and after intervention.
Difference between the intervention and control group in the change in urinary pH from baseline to the end of follow-up (4 weeks).
Change in urinary pH evaluated by the urine pH before and after intervention.
Full Information
NCT ID
NCT05375487
First Posted
May 11, 2022
Last Updated
May 11, 2022
Sponsor
Universidade Nova de Lisboa
Collaborators
CINTESIS - Center for Health Technology and Services Research
1. Study Identification
Unique Protocol Identification Number
NCT05375487
Brief Title
The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and on Gut Microbiota in Subjects With Functional Constipation: A Randomized, Placebo-Controlled Pilot Trial
Official Title
The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and on Gut Microbiota in Subjects With Functional Constipation: A Randomized, Placebo-Controlled Pilot Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 2022 (Anticipated)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universidade Nova de Lisboa
Collaborators
CINTESIS - Center for Health Technology and Services Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Functional constipation (FC) is a common condition associated with aging, lower socioeconomic status, low physical activity and also with reduced fibre, water and magnesium intakes. Different studies have reported a positive association between the intake of hyper-mineral water containing a high content of bicarbonate, calcium, or magnesium, and the improve of the gastrointestinal transit. There is evidence that magnesium and sulphate, both individually, have a laxative action. However, the impact of other minerals is scarce. It has been described different mechanisms explaining how gut microbiota influence the gastrointestinal transit. Specifically, in FC patients, it is important to understand the particularities of their gut microbiota and understand whether the intake of hyper-mineral water, a natural source of minerals, can modify positively the gut microbiota. The aim of the present randomized placebo-controlled pilot trial is to evaluate, for the first time, the effect of the carbonated mineral water consumption in the gastrointestinal transit and in the gut microbiota of subjects with FC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Constipation
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Carbonated Natural Mineral Water
Arm Type
Experimental
Arm Description
750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium and magnesium.
Arm Title
Low Mineral Water
Arm Type
Placebo Comparator
Arm Description
750 mL/day of low mineral water.
Intervention Type
Other
Intervention Name(s)
Carbonated Natural Mineral Water
Intervention Description
750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
Intervention Type
Other
Intervention Name(s)
Low Mineral Water
Intervention Description
750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
Primary Outcome Measure Information:
Title
Difference between the intervention and control group in the change in gastrointestinal transit from baseline to the end of follow-up (4 weeks).
Description
Change in gastrointestinal transit measured by the percentage of responder subjects defined as a composite score of the two following Rome IV criteria: number of stools ≥ 4 or an increase of 2 stools/week and stools consistency with less than 25% of lumpy to hard stools.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Difference between the intervention and control group in the change in stool consistency from baseline to the end of follow-up (4 weeks).
Description
Change in stool consistency measured using Bristol scale.
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in constipation symptoms from baseline to the end of follow-up (4 weeks).
Description
Change in constipation symptoms measured using a validated PAC-SYM questionnaire. PAC-SYM is a 12-item, self-administered questionnaire used to measure severity of symptoms over the past 2 weeks in patients with constipation. Cultural adaptation and linguistic validation of the PAC-SYM for Portugal was performed by Mapi Research.
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in constipation Quality of Life from baseline to the end of follow-up (4 weeks).
Description
Change in constipation Quality of Life measured using a validated PAC-QOL questionnaire. PAC-QOL questionnaire is a 28-item self-administered questionnaire that is being used to measure health-related quality of life (over the past 2 weeks) in patients with chronic constipation. Cultural adaptation and linguistic validation of the PAC-QOL for Portugal was performed by Mapi Research Trust.
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in Perceived Stress Scale from baseline to the end of follow-up (4 weeks).
Description
Change in constipation Perceived Stress Scale measured using a validated Perceived Stress Scale questionnaire. A validated Perceived Stress Scale (PSS) self-administered questionnaire with 13-item will be used to measure perceived stress of respondents during the last month (Portuguese version keeps 13 of the 14 original items). The PSS questionnaire has been demonstrated to have internal consistency, reproducibility, validity, and sensitivity. Cultural adaptation and linguistic validation of the PSS for Portugal was implemented by Pais-Ribeiro & Marques (2009).
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in gut microbiota from baseline to the end of follow-up (4 weeks).
Description
Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in short-chain fatty acid profiling from baseline to the end of follow-up (4 weeks).
Description
Change in short-chain fatty acid profiling evaluated by the faeces concentration of short-chain fatty acids before and after intervention.
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in urinary excretion of minerals from baseline to the end of follow-up (4 weeks).
Description
Change in urinary excretion of minerals evaluated by the K+, Na+, Mg2+ and Ca2+ excretion before and after intervention.
Time Frame
4 weeks
Title
Difference between the intervention and control group in the change in urinary pH from baseline to the end of follow-up (4 weeks).
Description
Change in urinary pH evaluated by the urine pH before and after intervention.
Time Frame
4 weeks
Other Pre-specified Outcome Measures:
Title
Adverse events
Description
Registration of any adverse events.
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 18 to 70
Having Functional Constipation diagnosis criteria, according to the Rome IV criteria
Not using any laxative drug for 3 days before screening visit
Drinking 1.0 ± 0.5 L of water per day
Accept and sign the consent
Exclusion Criteria:
Treatment or disease (current or past) likely to interfere with evaluation of the study parameters
Taking antibiotics in the 3 months preceding the recruitment visit
Taking supplements and any food enriched or presented containing bacteria or yeasts likely to have an effect on the gastrointestinal tract, particularly on intestinal transit, digestive comfort, gas production, the occurrence of abdominal pain in the 30 days preceding the recruitment visit (these products will also be banned during the study period)
Subject having an alcohol consumption of more than 3 glasses of wine a day, or 2 glasses of beer a day, or 1 glass of hard liquor a day
Subject having a coffee consumption greater than 5 cups per day
Subject with constipation attributable to an organic or anatomical cause (Hirschsprung's disease, hypothyroidism, mental deficiency, psychiatric illness, neurological abnormalities, history of operation of the colon or anus, colorectal cancer, anemia, etc.)
Subject with a history of current gastrointestinal pathology or disorder such as duodenal ulcer, chronic colitis, or chronic inflammatory disease of the gastrointestinal tract (Crohn's disease, ulcerative colitis), celiac disease or syndrome irritable bowel
Subject having a history of operation of the digestive tract
Subject having undergone surgery in the two months preceding the recruitment visit
Subject having undergone bariatric surgery
History of renal disease (renal insufficiency etc.) or cardiovascular disease (cardiac insufficiency...), respiratory disease, neural disease
Having participated in a weight loss program (with a 5-10% weight) loss in the last 3 months prior to the recruitment visit
Body mass index > 35 kg/ m2
Taking supplements of magnesium, vitamins, or other minerals during the study period
Intake of other carbonated mineral waters beyond the given water, during the study period.
Pregnancy
Participation in another clinical trial during the last 30 days prior to the recruitment visit
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Inês Mota
Phone
+351 218 803 053
Email
estudo.agua@nms.unl.pt
First Name & Middle Initial & Last Name or Official Title & Degree
André Rosário, PhD
Phone
+351 218 803 053
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Conceição Calhau, PhD
Organizational Affiliation
NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA de Lisboa
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
André Rosário, PhD
Organizational Affiliation
NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA de Lisboa
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Inês Mota
Organizational Affiliation
NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA de Lisboa
Official's Role
Study Director
Facility Information:
Facility Name
NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA
City
Lisbon
ZIP/Postal Code
1169-056
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Inês Mota
Email
estudo.agua@nms.unl.pt
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and on Gut Microbiota in Subjects With Functional Constipation: A Randomized, Placebo-Controlled Pilot Trial
We'll reach out to this number within 24 hrs